kireports.org
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays
the progression of chronic kidney disease (CKD), its effect on patients with autosomal
dominant polycystic kidney dis...